These findings are in agreement with those from Herzog et al indicating an upregulation of TP53 in HNSCC cell lines treated with the dual inhibitor PI3K/mTOR PF-04691502 [31]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.